New lung cancer treatments (immunotherapy and targeted therapies) and their associations with depression and other psychological side effects as compared to chemotherapy Journal Article


Author: McFarland, D. C.
Article Title: New lung cancer treatments (immunotherapy and targeted therapies) and their associations with depression and other psychological side effects as compared to chemotherapy
Abstract: Objective: Lung cancer carries a high prevalence of distress, anxiety and depression. New treatments, targeted therapy and immunotherapy have changed the disease course for subsets of patients and confer longer survival, but their psychological associations and possible mechanisms (e.g., inflammation and physical symptoms) are not well described. Method: Patients with metastatic lung cancer undergoing systemic treatment (n = 109) were evaluated for distress, self-endorsed problems using the Distress Thermometer and Problem List, and depression and anxiety using the Hospital Anxiety and Depression Scale. Demography, cancer-related information, and inflammation were evaluated for their associations with chemotherapy, targeted therapy, and immunotherapy. Inflammation was measured by C-reactive protein, albumin, and neutrophil to lymphocyte ratio. Results: Chemotherapies were given most often followed by immunotherapy and targeted therapies. Depression and anxiety were endorsed by 23.9%, respectively, and 41.1% had significant distress. Chemotherapy was associated with depression (p = .006) and inflammation (p < .001). Physical symptoms were the same among treatment types. Targeted therapy and immunotherapy predicted for less depression (p = .04, p = .04 respectively) than chemotherapy when controlling for age, sex, and performance status however these predictors where not significant when controlled for inflammation. Conclusion: New immunotherapy and targeted therapies are associated with less depression and inflammation among patients who are living longer while their physical symptoms are the same. © 2019 Elsevier Inc.
Keywords: cancer chemotherapy; cancer survival; controlled study; aged; major clinical study; disease course; bcg vaccine; interleukin 2; ipilimumab; cancer immunotherapy; melanoma; inflammation; lung cancer; bladder cancer; depression; lung metastasis; antidepressant agent; distress syndrome; anxiety; small cell lung cancer; molecularly targeted therapy; nivolumab; human; male; female; article; pembrolizumab; durvalumab; atezolizumab; avelumab; psychological well-being
Journal Title: General Hospital Psychiatry
Volume: 60
ISSN: 0163-8343
Publisher: Elsevier Science, Inc.  
Date Published: 2019-09-01
Start Page: 148
End Page: 155
Language: English
DOI: 10.1016/j.genhosppsych.2019.04.001
PUBMED: 31056371
PROVIDER: scopus
DOI/URL:
Notes: Source: Scopus
Altmetric Score
MSK Authors